title: Preclinical antitumor activity of SST0116CL1: a novel heat shock protein 90 inhibitor.
abstract: 4-Amino substituted resorcino-isoxazole (SST0116CL1) (property of Sigma-Tau Research Switzerland S.A.) is a potent, second generation, small-molecule heat shock protein 90 inhibitor (Hsp90i). SST0116CL1 binds to the ATP binding pocket of Hsp90, and interferes with Hsp90 chaperone function thus resulting in client protein degradation and tumor growth inhibition. The aim of the study was to assess SST0116CL1 in various solid and haematological tumors. The antitumor properties of SST0116CL1 were assessed using in vitro cell proliferation and client protein degradation assays and in vivo different tumor xenograft models. Pharmacokinetic (PK) data were also generated in tumor-bearing mice to gain an understanding of optimal dosing schedules and regimens. SST0116CL1 was shown to inhibit recombinant Hsp90α and to induce the destabilization of different client proteins, often overexpressed and constitutively activated in different types of hematological or solid human tumors. In preclinical in vivo studies, it was revealed to induce antitumor effects in murine models of leukemia and of gastric and ovarian carcinoma. A modulation of PD biomarkers in terms of downregulation of Hsp90 client proteins in tumor-bearing mice was found. SST0116CL1 is a new clinical candidate for cancer therapy. The antitumor property of SST0116CL1, likely due to direct inhibition of the Hsp90 enzymatic activity, may prove to be a critical attribute as the compound enters phase I clinical trials.
authors.affiliation: Research & Development, Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Pomezia, Italy.
authors.forename: Loredana
authors.initials: L
authors.lastname: Vesci
authors.affiliation: Research & Development, Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Pomezia, Italy.
authors.forename: Ferdinando Maria
authors.initials: FM
authors.lastname: Milazzo
authors.affiliation: Research & Development, Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Pomezia, Italy.
authors.forename: Valeria
authors.initials: V
authors.lastname: Carollo
authors.affiliation: Research & Development, Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Pomezia, Italy.
authors.forename: Silvia
authors.initials: S
authors.lastname: Pace
authors.affiliation: Research & Development, Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Pomezia, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Giannini
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors*; D006801:Humans; D007555:Isoxazoles / Q000494:pharmacology*; D051379:Mice; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism; D012118:Resorcinols / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D018841:HSP90 Heat-Shock Proteins; D007555:Isoxazoles; D012118:Resorcinols; C000598425:SST0116CL1
references.citation: Adv Pharmacol. 2012;65:471-517
references.pmid: 22959035
references.citation: Nat Rev Cancer. 2005 Oct;5(10):761-72
references.pmid: 16175177
references.citation: Oncol Rep. 2010 Jun;23(6):1483-92
references.pmid: 20428801
references.citation: Curr Top Med Chem. 2009;9(15):1479-92
references.pmid: 19860730
references.citation: BMC Cancer. 2013 Mar 25;13:152
references.pmid: 23530663
references.citation: Cancer Res. 2008 Apr 15;68(8):2850-60
references.pmid: 18413753
references.citation: Breast Cancer Res. 2008;10(2):R33
references.pmid: 18430202
references.citation: Curr Opin Investig Drugs. 2010 Dec;11(12):1466-76
references.pmid: 21154128
references.citation: Nat Rev Cancer. 2010 Aug;10(8):537-49
references.pmid: 20651736
references.citation: Cancer Res. 2001 May 15;61(10):4003-9
references.pmid: 11358818
references.citation: Cell Mol Life Sci. 2002 Oct;59(10):1640-8
references.pmid: 12475174
references.citation: Clin Cancer Res. 2007 Mar 15;13(6):1769-74
references.pmid: 17363531
references.citation: Clin Cancer Res. 2009 Dec 15;15(24):7471-7478
references.pmid: 20008847
references.citation: Mol Cancer Ther. 2009 Apr;8(4):921-9
references.pmid: 19372565
references.citation: Cancer Res. 2003 Nov 1;63(21):7345-55
references.pmid: 14612533
references.citation: J Clin Oncol. 2010 Mar 20;28(9):1520-6
references.pmid: 20177028
references.citation: Biochim Biophys Acta. 2012 Mar;1823(3):624-35
references.pmid: 21951723
references.citation: Blood. 2009 Jan 22;113(4):846-55
references.pmid: 18948577
references.citation: Biomed J. 2013 May-Jun;36(3):106-17
references.pmid: 23806880
references.citation: Expert Opin Drug Discov. 2011 May;6(5):559-587
references.pmid: 22400044
references.citation: Nat Rev Cancer. 2002 Jan;2(1):48-58
references.pmid: 11902585
references.citation: J Med Chem. 2011 Dec 22;54(24):8592-604
references.pmid: 22066525
references.citation: J Biol Chem. 1996 Sep 13;271(37):22796-801
references.pmid: 8798456
references.citation: Clin Cancer Res. 2013 Jul 1;19(13):3671-80
references.pmid: 23757357
references.citation: Br J Cancer. 2009 May 19;100(10):1523-9
references.pmid: 19401686
references.citation: Curr Opin Hematol. 2002 Jul;9(4):274-81
references.pmid: 12042700
references.citation: Curr Pharm Des. 2013;19(3):366-76
references.pmid: 22920907
references.citation: Oncologist. 2011;16(8):1162-74
references.pmid: 21765192
references.citation: J Natl Cancer Inst. 1999 Nov 17;91(22):1940-9
references.pmid: 10564678
references.citation: Clin Cancer Res. 2005 Jul 15;11(14):5281-91
references.pmid: 16033847
references.citation: Exp Hematol. 2008 Oct;36(10):1266-77
references.pmid: 18657349
references.citation: Cancer Res. 2008 Sep 15;68(18):7419-27
references.pmid: 18794130
references.citation: J Clin Oncol. 2005 Jun 20;23(18):4152-61
references.pmid: 15961763